Gilead Australia Medical Fellowships open for applications
Celebrating 15 years of supporting Australian led research in patient care
Melbourne, Australia [18 March 2026] – For 15 years, the Gilead Australia Medical Fellowships have supported Australian led clinical research focused on generating evidence to support improved patient outcomes in real world healthcare settings.
Since its inception, the program has awarded more than $4 million* to Australian led research initiatives, focusing on strengthening models of care, addressing unmet medical needs, and reducing barriers to diagnosis and treatment across communities throughout Australia.
The Fellowships support research projects across priority disease areas including HIV, chronic viral hepatitis, and hematological malignancies. Funded projects emphasise locally relevant approaches to care, with a particular focus on applied research intended to inform clinical practice, healthcare delivery, and patient education in Australian healthcare settings.
“Improving health outcomes requires more than scientific breakthroughs alone,” said Paul Slade, Medical Director, Gilead Australia. “It also means actively supporting innovative, locally driven, evidence-based solutions that help strengthen our healthcare systems and improve the experiences and outcomes of people and patients in everyday practice.”
Applications for the 2027 Gilead Australia Medical Fellowships are now open to eligible Australian researchers, healthcare professionals and multidisciplinary teams undertaking projects aligned with the program’s priority disease areas. Further information on eligibility criteria, research focus areas and the application process is available on the Gilead Sciences Australia website. https://www.gilead.com/en-au/responsibility/giving/gilead-australia-fellowship. Applications close on 14 May 2026, with fellowship recipients expected to be announced in July this year.
Gilead Sciences is a biopharmaceutical company that supports research and partnerships aimed at addressing some of the world’s most serious diseases and broader challenges affecting how care is delivered. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
* includes funding to be awarded through 2026.
END
Since its inception, the program has awarded more than $4 million* to Australian led research initiatives, focusing on strengthening models of care, addressing unmet medical needs, and reducing barriers to diagnosis and treatment across communities throughout Australia.
The Fellowships support research projects across priority disease areas including HIV, chronic viral hepatitis, and hematological malignancies. Funded projects emphasise locally relevant approaches to care, with a particular focus on applied research intended to inform clinical practice, healthcare delivery, and patient education in Australian healthcare settings.
“Improving health outcomes requires more than scientific breakthroughs alone,” said Paul Slade, Medical Director, Gilead Australia. “It also means actively supporting innovative, locally driven, evidence-based solutions that help strengthen our healthcare systems and improve the experiences and outcomes of people and patients in everyday practice.”
Applications for the 2027 Gilead Australia Medical Fellowships are now open to eligible Australian researchers, healthcare professionals and multidisciplinary teams undertaking projects aligned with the program’s priority disease areas. Further information on eligibility criteria, research focus areas and the application process is available on the Gilead Sciences Australia website. https://www.gilead.com/en-au/responsibility/giving/gilead-australia-fellowship. Applications close on 14 May 2026, with fellowship recipients expected to be announced in July this year.
Gilead Sciences is a biopharmaceutical company that supports research and partnerships aimed at addressing some of the world’s most serious diseases and broader challenges affecting how care is delivered. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
* includes funding to be awarded through 2026.
END